HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 14, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.

Via Benzinga

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

February 06, 2024

Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗

February 03, 2024

Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.

Via Talk Markets

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

February 02, 2024

HUTCHMED to Announce 2023 Final Results

February 01, 2024

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

January 29, 2024

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

January 10, 2024

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

December 12, 2023

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

November 30, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 24, 2023

Via Benzinga

Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know ↗

November 10, 2023

Via Benzinga

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

November 10, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

Virtual Investor Conference on November 8th and 9th, 2023

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

November 01, 2023

From Virtual Investor Conferences

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday ↗

October 27, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 24, 2023

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 ↗

October 16, 2023

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

October 16, 2023

U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session.

AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday ↗

October 11, 2023

Via Benzinga

Topics Stocks

Sarepta Therapeutics Stock Showing Rising Relative Strength ↗

October 09, 2023

Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

September 29, 2023

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗

September 28, 2023